Rothschild & Co Redburn analyst Natalya Davies initiated coverage of Waters (WAT) with a Buy rating and $390 price target The firm sees the life science equipment market returning to “normalized growth” of 4%-6% over the medium term, bolstered by persistent innovation in analytical instrumentation. The analyst sees upside in Waters due to the company’s acquisition of Becton Dickinson’s Biosciences and Diagnostics business. Rothschild views the deal as value-accretive.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WAT: